About Exousia Pro
Exousia Pro is a company based in St. Petersburg (United States) founded in 2024 was acquired by Medical Marijuana in January 2025. Exousia Pro has completed 1 acquisition, including Lamy. Exousia Pro offers products and services including Exosome Manufacturing Process and Proprietary Loading Technology. Exousia Pro operates in a competitive market with competitors including Modifi Bio, Biodexa Pharmaceuticals, OncoSynergy, CNS Pharmaceuticals and Plex Pharmaceuticals, among others.
- Headquarter St. Petersburg, United States
- SectorsHealthcare
- Phone•••• ••••
- Website exousiapro.com
- Social X
- Acquired by Medical Marijuana (Jan 2025)
- Investors
- Investments & Acquisitions
- Acquired byMedical Marijuana
(Jan 2025)
Products & Services of Exousia Pro
Exousia Pro offers a comprehensive portfolio of products and services, including Exosome Manufacturing Process and Proprietary Loading Technology.
Patented process using plant-based materials for exosome production.
Technology to infuse molecules like drugs and DNA into exosomes.
Investors in Exousia Pro
Exousia Pro has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Medical Marijuana.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manufacturer of cannabis focused products | 2009 | medicalmarijuanainc.com | San Diego, United States |
Investor details for Exousia Pro
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Exousia Pro
1 people are tracked at Exousia Pro (1 in leadership).
| Name | Role | Group |
|---|---|---|
Michael Sheikh | CEO | Leadership |
Complete people profiles for Exousia Pro
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Exousia Pro
Exousia Pro has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Lamy.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
High-quality writing instruments and digital tools are manufactured. | lamy.com | Frankfurt Am Main, Germany | 1930 | Nov 2025 | •••• |
Complete acquisition details for Exousia Pro
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Exousia Pro
3 dated milestones of Exousia Pro across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Exousia Pro is founded.
- Exit Acquired by Medical Marijuana.
- Acquisition Acquires Lamy.
Competitors of Exousia Pro
Exousia Pro operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Modifi Bio, Biodexa Pharmaceuticals, OncoSynergy, CNS Pharmaceuticals and Plex Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modifibio.com | 2021 | New Haven, United States | $11.7M | – | Developer of therapeutics for the treatment of cancer | |
| biodexapharma.com | 2000 | Cardiff, United Kingdom | $6.79M | – | Therapeutics for aggressive rare brain cancers are developed. | |
| oncosynergy.com | 2011 | San Francisco, United States | $26.71M | 3 | Resistance mechanism inhibitors for cancer treatment are developed. | |
| cnspharma.com | 2017 | Houston, United States | – | 5 | Treatments for brain and central nervous system cancers are developed. | |
| plexpharma.com | 2009 | San Diego, United States | – | – | Discovering small molecules for diseases caused by protein misfolding such as Parkinson's. | |
| flagtherapeutics.com | 2013 | Raleigh, United States | $1.37M | – | Small molecule therapeutics for difficult-to-treat cancers are developed. | |
| systimmune.com | 2014 | Redmond, United States | – | 36 | Develops therapeutic antibodies and ADCs to target cancer cells. | |
| purposeful.eu | 2000 | Athens, Greece | $293,896 | – | Purposeful is engaged in discovering treatments for rare diseases. | |
| diakonosoncology.com | 2022 | Houston, United States | $31.4M | – | Immunotherapeutics for various cancers are developed and provided by Diakonos. | |
| curtanapharma.com | 2013 | Austin, United States | – | – | Small molecule therapeutics targeting transcription factors for glioblastoma are developed. |
Detailed competitors of Exousia Pro
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Exousia Pro
10 companies that operate in the same segment as Exousia Pro (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Exousia Pro
Exousia Pro was founded in 2024.
Exousia Pro is headquartered in St. Petersburg, United States. It is registered at St. Petersburg, Florida, United States.
Michael Sheikh is the current CEO of Exousia Pro.
Exousia Pro was founded in 2024 and is based in St. Petersburg, United States. Operations in the biotechnology sector center on exosome-based therapeutics for cancer treatment. A mammalian exosomal technology platform is utilized, incorporating plant-derived materials to engineer exosomes targeted at glioblastoma. Development efforts focus on oncology applications, with leadership directed by CEO Michael Sheikh.
Exousia Pro's top competitors include Modifi Bio, Diakonos and Biodexa Pharmaceuticals.
Exousia Pro offers Exosome Manufacturing Process and Proprietary Loading Technology.
Exousia Pro has made 1 acquisition, including Lamy.
Exousia Pro has 1 investor. Key investors include Medical Marijuana.
Yes. Exousia Pro was acquired by Medical Marijuana in January 2025.